{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T11:03:15Z","timestamp":1788346995474,"version":"build-2803163510"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2023,4,27]],"date-time":"2023-04-27T00:00:00Z","timestamp":1682553600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,4,27]],"date-time":"2023-04-27T00:00:00Z","timestamp":1682553600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"DOI":"10.1007\/s10238-023-01082-5","type":"journal-article","created":{"date-parts":[[2023,4,27]],"date-time":"2023-04-27T10:02:06Z","timestamp":1682589726000},"page":"4817-4824","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Immune-related thyroid dysfunctions during anti PD-1\/PD-L1 inhibitors: new evidence from a single centre experience"],"prefix":"10.1007","volume":"23","author":[{"given":"Alice","family":"Nervo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Ferrari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Gruosso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrica","family":"Migliore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Basile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"D\u2019Angelo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Roux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Piovesan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuela","family":"Arvat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,27]]},"reference":[{"key":"1082_CR1","doi-asserted-by":"publisher","first-page":"101370","DOI":"10.1016\/j.beem.2019.101370","volume":"34","author":"G Elia","year":"2020","unstructured":"Elia G, Ferrari SM, Galdiero MR, et al. New insight in endocrine-related adverse events associated to immune checkpoint blockade. Best Pract Res Clin Endocrinol Metab. 2020;34:101370. https:\/\/doi.org\/10.1016\/j.beem.2019.101370.","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"1082_CR2","doi-asserted-by":"publisher","first-page":"886930","DOI":"10.3389\/fendo.2022.886930","volume":"13","author":"CA Muir","year":"2022","unstructured":"Muir CA, Tsang VHM, Menzies AM, Clifton-Bligh RJ. Immune related adverse events of the thyroid\u2014a narrative review. Front Endocrinol (Lausanne). 2022;13:886930. https:\/\/doi.org\/10.3389\/fendo.2022.886930.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"1082_CR3","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1002\/cncr.31200","volume":"124","author":"R Barroso-Sousa","year":"2018","unstructured":"Barroso-Sousa R, Ott PA, Hodi FS, et al. Endocrine dysfunction induced by immune checkpoint inhibitors: practical recommendations for diagnosis and clinical management. Cancer. 2018;124:1111\u201321. https:\/\/doi.org\/10.1002\/cncr.31200.","journal-title":"Cancer"},{"key":"1082_CR4","doi-asserted-by":"publisher","first-page":"413","DOI":"10.3803\/EnM.2020.906","volume":"36","author":"JH Yoon","year":"2021","unstructured":"Yoon JH, Hong AR, Kim HK, Kang H-C. Characteristics of immune-related thyroid adverse events in patients treated with PD-1\/PD-L1 inhibitors. Endocrinol Metab (Seoul). 2021;36:413\u201323. https:\/\/doi.org\/10.3803\/EnM.2020.906.","journal-title":"Endocrinol Metab (Seoul)"},{"key":"1082_CR5","doi-asserted-by":"publisher","first-page":"101660","DOI":"10.1016\/j.beem.2022.101660","volume":"36","author":"S Iwama","year":"2022","unstructured":"Iwama S, Kobayashi T, Yasuda Y, Arima H. Immune checkpoint inhibitor-related thyroid dysfunction. Best Pract Res Clin Endocrinol Metab. 2022;36:101660. https:\/\/doi.org\/10.1016\/j.beem.2022.101660.","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"1082_CR6","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1038\/s41416-020-0736-7","volume":"122","author":"N Okada","year":"2020","unstructured":"Okada N, Iwama S, Okuji T, et al. Anti-thyroid antibodies and thyroid echo pattern at baseline as risk factors for thyroid dysfunction induced by anti-programmed cell death-1 antibodies: a prospective study. Br J Cancer. 2020;122:771\u20137. https:\/\/doi.org\/10.1038\/s41416-020-0736-7.","journal-title":"Br J Cancer"},{"key":"1082_CR7","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1158\/2326-6066.CIR-17-0208","volume":"5","author":"H Lee","year":"2017","unstructured":"Lee H, Hodi FS, Giobbie-Hurder A, et al. Characterization of thyroid disorders in patients receiving immune checkpoint inhibition therapy. Cancer Immunol Res. 2017;5:1133\u201340. https:\/\/doi.org\/10.1158\/2326-6066.CIR-17-0208.","journal-title":"Cancer Immunol Res"},{"key":"1082_CR8","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1089\/thy.2021.0685","volume":"32","author":"T Mosaferi","year":"2022","unstructured":"Mosaferi T, Tsai K, Sovich S, et al. Optimal thyroid hormone replacement dose in immune checkpoint inhibitor-associated hypothyroidism is distinct from Hashimoto\u2019s thyroiditis. Thyroid. 2022;32:496\u2013504. https:\/\/doi.org\/10.1089\/thy.2021.0685.","journal-title":"Thyroid"},{"key":"1082_CR9","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1007\/s40618-020-01480-6","volume":"44","author":"L Brilli","year":"2021","unstructured":"Brilli L, Danielli R, Campanile M, et al. Baseline serum TSH levels predict the absence of thyroid dysfunction in cancer patients treated with immunotherapy. J Endocrinol Invest. 2021;44:1719\u201326. https:\/\/doi.org\/10.1007\/s40618-020-01480-6.","journal-title":"J Endocrinol Invest"},{"key":"1082_CR10","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1007\/s00262-021-03128-7","volume":"71","author":"Y-MM Cheung","year":"2022","unstructured":"Cheung Y-MM, Wang W, McGregor B, Hamnvik O-PR. Associations between immune-related thyroid dysfunction and efficacy of immune checkpoint inhibitors: a systematic review and meta-analysis. Cancer Immunol Immunother. 2022;71:1795\u2013812. https:\/\/doi.org\/10.1007\/s00262-021-03128-7.","journal-title":"Cancer Immunol Immunother"},{"key":"1082_CR11","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228\u201347. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026.","journal-title":"Eur J Cancer"},{"key":"1082_CR12","doi-asserted-by":"publisher","first-page":"e199","DOI":"10.1016\/j.lpm.2018.10.019","volume":"48","author":"P Campredon","year":"2019","unstructured":"Campredon P, Mouly C, Lusque A, et al. Incidence of thyroid dysfunctions during treatment with nivolumab for non-small cell lung cancer: Retrospective study of 105 patients. Presse Med. 2019;48:e199\u2013207. https:\/\/doi.org\/10.1016\/j.lpm.2018.10.019.","journal-title":"Presse Med"},{"key":"1082_CR13","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1007\/s12020-019-01871-7","volume":"64","author":"I Peir\u00f3","year":"2019","unstructured":"Peir\u00f3 I, Palmero R, Iglesias P, et al. Thyroid dysfunction induced by nivolumab: searching for disease patterns and outcomes. Endocrine. 2019;64:605\u201313. https:\/\/doi.org\/10.1007\/s12020-019-01871-7.","journal-title":"Endocrine"},{"key":"1082_CR14","doi-asserted-by":"publisher","first-page":"G1","DOI":"10.1530\/ERC-18-0320","volume":"26","author":"F Castinetti","year":"2019","unstructured":"Castinetti F, Albarel F, Archambeaud F, et al. French endocrine society guidance on endocrine side effects of immunotherapy. Endocr Relat Cancer. 2019;26:G1\u201318. https:\/\/doi.org\/10.1530\/ERC-18-0320.","journal-title":"Endocr Relat Cancer"},{"key":"1082_CR15","doi-asserted-by":"publisher","first-page":"G1","DOI":"10.1530\/EJE-22-0689","volume":"187","author":"ES Husebye","year":"2022","unstructured":"Husebye ES, Castinetti F, Criseno S, et al. Endocrine-related adverse conditions in patients receiving immune checkpoint inhibition: an ESE clinical practice guideline. Eur J Endocrinol. 2022;187:G1\u201321. https:\/\/doi.org\/10.1530\/EJE-22-0689.","journal-title":"Eur J Endocrinol"},{"key":"1082_CR16","doi-asserted-by":"publisher","first-page":"295","DOI":"10.2174\/1381612828666220518151509","volume":"29","author":"A Patrizio","year":"2023","unstructured":"Patrizio A, Fallahi P, Antonelli A, Ferrari SM. Immune checkpoint inhibitor-induced thyroid disorders: a single center experience. Curr Pharm Des. 2023;29:295\u20139. https:\/\/doi.org\/10.2174\/1381612828666220518151509.","journal-title":"Curr Pharm Des"},{"key":"1082_CR17","doi-asserted-by":"publisher","first-page":"824","DOI":"10.4158\/EP-2018-0472","volume":"25","author":"RM Pollack","year":"2019","unstructured":"Pollack RM, Kagan M, Lotem M, Dresner-Pollak R. Baseline TSH level is associated with risk of ANTI-PD-1-induced thyroid dysfunction. Endocr Pract. 2019;25:824\u20139. https:\/\/doi.org\/10.4158\/EP-2018-0472.","journal-title":"Endocr Pract"},{"key":"1082_CR18","doi-asserted-by":"publisher","first-page":"3583","DOI":"10.1111\/cas.13800","volume":"109","author":"S Kimbara","year":"2018","unstructured":"Kimbara S, Fujiwara Y, Iwama S, et al. Association of antithyroglobulin antibodies with the development of thyroid dysfunction induced by nivolumab. Cancer Sci. 2018;109:3583\u201390. https:\/\/doi.org\/10.1111\/cas.13800.","journal-title":"Cancer Sci"},{"key":"1082_CR19","doi-asserted-by":"publisher","first-page":"100415","DOI":"10.1016\/j.esmoop.2022.100415","volume":"7","author":"N Izawa","year":"2022","unstructured":"Izawa N, Shiokawa H, Onuki R, et al. The clinical utility of comprehensive measurement of autoimmune disease-related antibodies in patients with advanced solid tumors receiving immune checkpoint inhibitors: a retrospective study. ESMO Open. 2022;7:100415. https:\/\/doi.org\/10.1016\/j.esmoop.2022.100415.","journal-title":"ESMO Open"},{"key":"1082_CR20","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1089\/thy.2019.0250","volume":"30","author":"A Kotwal","year":"2020","unstructured":"Kotwal A, Kottschade L, Ryder M. PD-L1 inhibitor-induced thyroiditis is associated with better overall survival in cancer patients. Thyroid. 2020;30:177\u201384. https:\/\/doi.org\/10.1089\/thy.2019.0250.","journal-title":"Thyroid"},{"key":"1082_CR21","doi-asserted-by":"publisher","first-page":"e1843","DOI":"10.1210\/clinem\/dgac059","volume":"107","author":"CA Muir","year":"2022","unstructured":"Muir CA, Wood CCG, Clifton-Bligh RJ, et al. Association of antithyroid antibodies in checkpoint inhibitor-associated thyroid immune-related adverse events. J Clin Endocrinol Metab. 2022;107:e1843\u20139. https:\/\/doi.org\/10.1210\/clinem\/dgac059.","journal-title":"J Clin Endocrinol Metab"},{"key":"1082_CR22","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s00262-020-02664-y","volume":"70","author":"J Lima Ferreira","year":"2021","unstructured":"Lima Ferreira J, Costa C, Marques B, et al. Improved survival in patients with thyroid function test abnormalities secondary to immune-checkpoint inhibitors. Cancer Immunol Immunother. 2021;70:299\u2013309. https:\/\/doi.org\/10.1007\/s00262-020-02664-y.","journal-title":"Cancer Immunol Immunother"},{"key":"1082_CR23","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1097\/MED.0000000000000664","volume":"28","author":"A Kotwal","year":"2021","unstructured":"Kotwal A, Ryder M. Survival benefit of endocrine dysfunction following immune checkpoint inhibitors for nonthyroidal cancers. Curr Opin Endocrinol Diabetes Obes. 2021;28:517\u201324. https:\/\/doi.org\/10.1097\/MED.0000000000000664.","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"1082_CR24","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1097\/CMR.0000000000000739","volume":"31","author":"A Frelau","year":"2021","unstructured":"Frelau A, Jali E, Campillo-Gimenez B, et al. Prognostic impact of thyroid dysfunctions on progression-free survival in patients with metastatic melanoma treated with anti-PD-1 antibodies. Melanoma Res. 2021;31:208\u201317. https:\/\/doi.org\/10.1097\/CMR.0000000000000739.","journal-title":"Melanoma Res"},{"key":"1082_CR25","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s13244-021-00968-w","volume":"12","author":"IK Yirgin","year":"2021","unstructured":"Yirgin IK, Erturk SM, Dogan I, Vatansever S. Are radiologists ready to evaluate true response to immunotherapy? Insights Imaging. 2021;12:29. https:\/\/doi.org\/10.1186\/s13244-021-00968-w.","journal-title":"Insights Imaging"},{"key":"1082_CR26","doi-asserted-by":"publisher","first-page":"e143","DOI":"10.1016\/S1470-2045(17)30074-8","volume":"18","author":"L Seymour","year":"2017","unstructured":"Seymour L, Bogaerts J, Perrone A, et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol. 2017;18:e143\u201352. https:\/\/doi.org\/10.1016\/S1470-2045(17)30074-8.","journal-title":"Lancet Oncol"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-023-01082-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-023-01082-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-023-01082-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,16]],"date-time":"2023-12-16T16:04:46Z","timestamp":1702742686000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10238-023-01082-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,27]]},"references-count":26,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1082"],"URL":"https:\/\/doi.org\/10.1007\/s10238-023-01082-5","relation":{},"ISSN":["1591-9528"],"issn-type":[{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,27]]},"assertion":[{"value":"1 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None of the authors have competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}},{"value":"The study was approved by the local ethics board committee (protocol number 0033240) and was in accordance with the principles of Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}]}}